Search Results - ligand

3 Results Sort By:
Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction
This technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein...
Published: 10/28/2024   |   Inventor(s): Noel Southall, Marc Ferrer-Alegre, Daniel Jansen, Mark Henderson, Xin Hu, David Kim, Juan Marugan
Keywords(s): ADDICTION, Chemical, FOOD, Funtionally, Ghrelin, LIGAND, NCG00538279, Novel, RECEPTOR, SELECTIVE, treatment, VEXXXX, VGXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Neurology, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Research Materials
CD40 Ligand: Adjuvant for Enhanced Immune Response to Respiratory Syncytial Virus
CDC researchers have developed methods and adjuvants for enhancing a subject's immune response to respiratory syncytial virus (RSV) by inclusion of a CD40 binding protein. RSV has long been recognized as a major respiratory tract pathogen of infants, as well as older children and the elderly. Established, successful methods for preventing RSV are...
Published: 4/8/2024   |   Inventor(s): Larry Anderson, Michael Brown, Ralph Tripp
Keywords(s): adjuvant, CD40, CD40L, CDC Docket Import, CDC Docket Import CDC Prosecuting, Costimulation, COSTIMULATORY, DB4BXX, DB4XXX, DBXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, LIGAND, OID-NCIRD-DVD, respiratory, RSV, RSV virus, Synctial, Vacccination, Vaccine, virus, VLXXXX, WJXXXX, YBXXXX, YCXXXX
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines
HM74A/HM74 Ligands as Anti-Cancer and Anti-Diarrheal Drugs
Tech ID: 2007-030: Compositions Comprising a GPR109 Ligand for Treating Disorders of the Digestive Tract and/or CancerState of the Art: Top drugs for colon cancer include Xeloda (Genetech), Erbitux (Johnson and Johnson), Eloxatin (Sanofi), and Gleevec (Novartis). These four drugs ranked in the top 10 selling cancer drugs of 2011 and totaled ~$4 billion...
Published: 10/5/2020   |   Inventor(s): Vadivel Ganapathy, Puttur Prasad, Muthusamy Thangaraju, Gail Cresci
Keywords(s): Colon Cancer, Gene, Ligand
Category(s): Therapeutics